Form 8-K - Current report:
SEC Accession No. 0001628280-22-027966
Filing Date
2022-11-03
Accepted
2022-11-03 07:21:04
Documents
14
Period of Report
2022-11-03
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cccc-20221103.htm   iXBRL 8-K 38737
2 EX-99.1 cccc-20221103xexx991.htm EX-99.1 59968
6 image_0.jpg GRAPHIC 117845
  Complete submission text file 0001628280-22-027966.txt   412130

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cccc-20221103.xsd EX-101.SCH 1946
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cccc-20221103_lab.xml EX-101.LAB 24849
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cccc-20221103_pre.xml EX-101.PRE 13086
8 EXTRACTED XBRL INSTANCE DOCUMENT cccc-20221103_htm.xml XML 12847
Mailing Address 490 ARSENAL WAY SUITE 200 WATERTOWN MA 02472
Business Address 490 ARSENAL WAY SUITE 200 WATERTOWN MA 02472 (617) 231-0700
C4 Therapeutics, Inc. (Filer) CIK: 0001662579 (see all company filings)

EIN.: 475617627 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39567 | Film No.: 221356210
SIC: 2836 Biological Products, (No Diagnostic Substances)